Bio

• Experienced Scientist with 14+ years of expertise in Clinical and Translational Research, Biocompatible Invasive Biomedical Devices, In vitro Biology, FDA approved Immunotherapeutic (Cancer and Autoimmune disorders), Bioprocess Development, Antibacterial, and Antithrombotic Biomaterials, Tissue Engineering applications, Macro and Microencapsulation technology for making artificial pancreas for Type 1 Diabetes (T1D) treatment. • Experienced in Business Development (BD) and Product Development (PD). As the Co-founder and Director (2018-2020) of Biomedical Startup: Lead Innoveta Biomedical LLC, GA; attracted funding from NIH, CDC, GRA, and US DoD. Tech transfer for commercialization. • Worked in Multinational and Multicultural Environment 4 major companies and 8 R1 Academic Research Institutions in India, Germany, and the US. (Doctoral Valedictorian) • Innovator and Highly Productive Researcher with 7 patent applications filed at USPTO (4 approved), • Excellent Oral and Written Communications Skills demonstrated through 18 Scientific Conferences, 25 peer-reviewed Publications, 4 Conference Abstracts (achieved in 5 years); >50 Grant Authored and Submission; Editorial Board member for 5 journals • Establish Experts in Translational & Clinical Research with 2 TEDx talks, Features in 11 Leading News Papers, 1 Podcast, and 2 Magazine Articles, and >20 invited Capacity Building Seminars as Keynote • Production, cGMP, and FDA Approval: Contributed to the upstream process development of the world's first anti-CD6 monoclonal antibody for Psoriasis treatment (Alzumab/Itolizumab) and the world's first biosimilar for Herceptin (Canmab) for breast cancer treatment both of which are now FDA approved. Itolizumab is current used in India for treating COVID-19 complications. —Biocon Research Ltd+Mylan